China SXT Pharmaceuticals (SXTC) Financial Statements & Analysis

China SXT Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

China SXT Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Revenue & Gross Profit
Revenue	1.14	1.74	1.93	1.97	2.60	4.78	5.16	7.01	7.02	4.88
Cost of Revenue	0.89	1.37	1.37	1.55	1.35	1.94	2.46	2.40	3.62	2.57
Gross Profit	0.25	0.37	0.55	0.43	1.25	2.84	2.70	4.61	3.40	2.31
Operating Expenses
Research & Development	0.18	0.19	0.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling, General & Administrative	7.37	3.05	3.07	5.68	6.44	5.04	4.04	2.84	1.77	0.71
Operating Expenses	7.37	3.05	3.07	6.03	6.44	5.04	4.04	2.84	1.77	0.71
Operating Income	-7.12	-2.68	-2.52	-5.61	-5.19	-2.20	-1.34	1.77	1.63	1.60
Other Income/Expense
Interest Income	0.00	0.19	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.06	-0.84	0.54	-0.48	-0.04	1.62	3.35	0.01	0.00	0.04
Other Income/Expense	0.92	-0.62	-0.04	-0.33	-0.22	-0.74	-9.05	0.02	0.00	-0.02
Income
Income Before Tax	-6.21	-3.30	-3.10	-5.93	-5.41	-2.94	-10.39	1.79	1.63	1.58
Income Tax Expense	0.13	0.00	0.00	0.00	-0.33	-0.19	-0.10	0.25	0.44	0.40
Net Income	-6.21	-3.30	-3.10	-5.93	-5.74	-2.75	-10.29	1.54	1.19	1.19
Net Income - Continuous Operations	-6.21	-3.30	-3.10	-5.93	-5.74	-2.75	-10.29	1.54	1.19	1.19
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-
EBITDA	-7.05	-2.60	-2.28	-5.01	-4.87	-1.85	-1.01	1.98	1.76	1.70
EBIT	-7.12	-2.68	-2.55	-5.26	-5.19	-2.20	-	-	-	-
Depreciation & Amortization	0.14	0.08	0.27	0.25	0.32	0.35	0.33	0.18	0.13	0.10
Earnings Per Share
Basic EPS	-9.00	-2.00	-134719.00	-178.00	-3.00	-95.00	-832.00	150.00	100.00	100.00
Diluted EPS	-9.00	-2.00	-134719.00	-178.00	-1103.00	-95.00	-832.00	150.00	100.00	100.00
Basic Shares Outstanding	0.68	1.42	0.00	0.03	2.03	0.03	0.01	0.01	0.01	0.01
Diluted Shares Outstanding	0.68	1.42	0.00	0.03	2.03	0.03	0.01	0.01	0.01	0.01

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About China SXT Pharmaceuticals Financial Statements

What was China SXT Pharmaceuticals's revenue in fiscal 2026?

China SXT Pharmaceuticals reported revenue of $1.14M in fiscal 2026 (fiscal year ended Mar 31, 2026). That was down 34.6% from $1.74M a year earlier.

Is China SXT Pharmaceuticals profitable?

No. China SXT Pharmaceuticals reported a net loss of $6.21M in fiscal 2026. In fiscal 2025 it lost $3.30M.

What is China SXT Pharmaceuticals's operating margin?

China SXT Pharmaceuticals's operating income was −$7.12M on revenue of $1.14M in fiscal 2026, an operating margin of -625.9%, compared with -154.0% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition